Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947744639> ?p ?o ?g. }
Showing items 1 to 54 of
54
with 100 items per page.
- W2947744639 endingPage "6645" @default.
- W2947744639 startingPage "6645" @default.
- W2947744639 abstract "6645 Background: Pegfilgrastim (pegfil) injection is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Assuming biosimilarity of biosim-pegfil and pegfil in the prevention of febrile neutropenia, we estimated cost minimization of conversion from pegfil to biosim-pegfil and subsequent potential expanded access due to cost savings. Methods: A cost minimization model was conducted based on a hypothetical panel of 20,000 patients using average selling price (ASP) for one chemotherapy cycle. ASP was obtained from 1Q 2019 payment allowance limits. The simulation included two steps: 1) cost minimization was calculated per cycle (biosim-pegfil and pegfil is administered 1 dose per cycle) when patients were converted to biosim-pegfil from pegfil on ratio of 10% to 100% at 10% intervals and at a discount from 15% to 35% at 5% intervals, and 2) expanded access to biosim-pegfil was calculated based on budget neutrality. Since pegfil has two forms of availability (Neulasta and Neulasta-Onpro) with the same price, results were to either conversion scenario. Results: Per-cycle per-patient cost minimization from converting pegfil to biosim-pegfil ranged from $702.27 (15% discount) to $1,638.63 (35% discount). For 20,000 patients, this yields savings of over $14 million (15% discount) to $32 million (35% discount) at 100% conversion rate. When half the patients were converted to biosim-pegfil, savings could range from > $7 million (15% discount) to > $16 million (35% discount). With 100% conversion rate and 15% discount, 3,529 additional patients could be treated with the savings generated. At 50% conversion rate, cost savings could be applied to another 1,765 patients with 15% discount, 3,333 patients with 25% discount, and 5,385 patients with 35% discount, respectively. Conclusions: Conversion from pegfil to biosim-pegfil can lead to potential cost savings and these savings can be applied to offer increased access to supportive care with biosim-pegfil for patients receiving chemotherapy on a budget-neutral basis. For payers with larger populations, savings can be substantial. More studies are warranted to evaluate such potential cost savings due to use of biosim-pegfil over reference pegfil." @default.
- W2947744639 created "2019-06-07" @default.
- W2947744639 creator A5019554240 @default.
- W2947744639 creator A5028393157 @default.
- W2947744639 creator A5090217932 @default.
- W2947744639 date "2019-05-20" @default.
- W2947744639 modified "2023-09-25" @default.
- W2947744639 title "Cost-minimization analysis for biosimilar pegfilgrastim in the prophylaxis of chemotherapy induced (febrile) neutropenia and expanded access based on budget neutral basis." @default.
- W2947744639 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.6645" @default.
- W2947744639 hasPublicationYear "2019" @default.
- W2947744639 type Work @default.
- W2947744639 sameAs 2947744639 @default.
- W2947744639 citedByCount "0" @default.
- W2947744639 crossrefType "journal-article" @default.
- W2947744639 hasAuthorship W2947744639A5019554240 @default.
- W2947744639 hasAuthorship W2947744639A5028393157 @default.
- W2947744639 hasAuthorship W2947744639A5090217932 @default.
- W2947744639 hasConcept C126322002 @default.
- W2947744639 hasConcept C2776694085 @default.
- W2947744639 hasConcept C2777063308 @default.
- W2947744639 hasConcept C2778658803 @default.
- W2947744639 hasConcept C2778850193 @default.
- W2947744639 hasConcept C2779171977 @default.
- W2947744639 hasConcept C59491497 @default.
- W2947744639 hasConcept C71924100 @default.
- W2947744639 hasConceptScore W2947744639C126322002 @default.
- W2947744639 hasConceptScore W2947744639C2776694085 @default.
- W2947744639 hasConceptScore W2947744639C2777063308 @default.
- W2947744639 hasConceptScore W2947744639C2778658803 @default.
- W2947744639 hasConceptScore W2947744639C2778850193 @default.
- W2947744639 hasConceptScore W2947744639C2779171977 @default.
- W2947744639 hasConceptScore W2947744639C59491497 @default.
- W2947744639 hasConceptScore W2947744639C71924100 @default.
- W2947744639 hasIssue "15_suppl" @default.
- W2947744639 hasLocation W29477446391 @default.
- W2947744639 hasOpenAccess W2947744639 @default.
- W2947744639 hasPrimaryLocation W29477446391 @default.
- W2947744639 hasRelatedWork W1977463315 @default.
- W2947744639 hasRelatedWork W2252900637 @default.
- W2947744639 hasRelatedWork W2322588233 @default.
- W2947744639 hasRelatedWork W2411253176 @default.
- W2947744639 hasRelatedWork W2769130234 @default.
- W2947744639 hasRelatedWork W2936044229 @default.
- W2947744639 hasRelatedWork W3010100147 @default.
- W2947744639 hasRelatedWork W3207612165 @default.
- W2947744639 hasRelatedWork W338893720 @default.
- W2947744639 hasRelatedWork W4205589333 @default.
- W2947744639 hasVolume "37" @default.
- W2947744639 isParatext "false" @default.
- W2947744639 isRetracted "false" @default.
- W2947744639 magId "2947744639" @default.
- W2947744639 workType "article" @default.